Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene Fusions

Conversion to regular approval is based on data from additionally included patients and additional follow-up in the ARROW study
01 Sep 2023
Targeted Therapy;  Genetic and Genomic Testing
Non-Small Cell Lung Cancer

On 9 August 2023, the US Food and Drug Administration (FDA) granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Pralsetinib was previously granted accelerated approval for the NSCLC indication on 4 September 2020, based on initial overall response rate (ORR) and duration of response (DoR) in 114 patients enroled in the ARROW (NCT03037385), a multicentre, open-label, multi-cohort study. The conversion to regular approval was based on data from an additional 123 patients and 25 months of additional follow-up to assess durability of response.

Full prescribing information for Gavreto is available here.

Efficacy was demonstrated in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC. Patients received pralsetinib until disease progression or unacceptable toxicity.

The primary efficacy measures were ORR and DoR as determined by a Blinded Independent Review Committee. Among 107 treatment-naïve patients, ORR was 78% (95% confidence interval [CI] 68, 85) with a median DoR of 13.4 months (95% CI 9.4, 23.1). Among 130 patients previously treated with platinum-based chemotherapy, ORR was 63% (95% CI 54, 71) with a median DoR of 38.8 months (95% CI 14.8, not estimable).

The most common adverse reactions (≥25%) were musculoskeletal pain, constipation, hypertension, diarrhoea, fatigue, oedema, pyrexia, and cough.

The recommended pralsetinib dose is 400 mg orally once daily. Pralsetinib is taken on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking pralsetinib).

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted breakthrough designation and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.